secwatch.observer — SEC 8-K summary
======================================

Issuer:     Mosaic ImmunoEngineering Inc. (CPMV)
CIK:        0000836564
Form:       8-K
Filed at:   2024-04-29T23:59:59+00:00
Accession:  0001683168-24-002761
Event type: m_and_a
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Mosaic to acquire Oncotelic's clinical necroptosis cancer assets for up to $30M in stock
--------------------------------------------------------------------------------

- Binding term sheet signed April 26, 2024; acquisition includes VDA necroptosis therapies and AI platform.
- Initial $15M in common or preferred stock; milestone payments up to $15M more in shares.
- Oncotelic to provide operational loan through June 1 and assist in raising $2M initial funding.
- If funding fails, transaction may convert to reverse acquisition/merger; shareholder approval required.
- Mosaic gains regulatory packages and access to Oncotelic's AI for immunotherapy combination discovery.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/836564/000168316824002761/0001683168-24-002761-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/836564/000168316824002761/mosaic_8k.htm
  HTML page:      https://secwatch.observer/filing/0001683168-24-002761

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer